X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is being evaluated for the treatment of moderate Parkinson’s Disease.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
The proceeds will be used to advance NKGen's SNK01, an autologous NK cell therapy candidate, for phase 2 alzheimer’s clinical trial and the company has recently submitted IND for parkinson’s disease.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 11, 2024
Details:
SNK01 is a first-in-kind, autologous non-genetically modified NK cell product with significant anti-tumor cytotoxicity. It is being evaluated for the treatment of Alzheimer’s disease.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is being evaluated in phase 1/2 clinical trials for the treatment of moderate Alzheimer’s Disease.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2023
Details:
SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is being evaluated in phase 1/2 clinical trials for the treatment of moderate Alzheimer’s Disease.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is investigated for the treatment of moderate Alzheimer’s Disease.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
SNK01 is currently in Phase 1 trial in Mexico for the treatment of advanced Alzheimer’s disease and two Phase 1/2 trials in the US for advanced refractory solid tumors as a monotherapy and in combination with other agents including checkpoint inhibitors and cell engagers.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Graf Acquisition Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 02, 2023
Details:
SNK02, allogeneic blood-derived NK cell therapy and will be administered as an intravenous infusion, which is investigated for treatment of solid tumors.
Lead Product(s): SNK02
Therapeutic Area: Oncology Product Name: SNK02
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
SNK01 is currently in Phase 1 trial in Mexico for the treatment of advanced Alzheimer’s disease and two Phase 1/2 trials in the US for advanced refractory solid tumors as a monotherapy and in combination with other agents including checkpoint inhibitors and cell engagers.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Graf Acquisition Corp. IV
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 14, 2023
Details:
NKGen Biotech's non-genetically modified, enhanced, and expanded NK cells (SNK01) is currently in clinical trials for advanced refractory solid tumors both as a monotherapy and in combination with other agents, including checkpoint inhibitors and cell engagers.
Lead Product(s): SNK01
Therapeutic Area: Neurology Product Name: SNK01
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Parkinson’s Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
